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Metastatic colonization of distant organs under-
pins the majority of human-cancer-related deaths,
including deaths from head and neck squamous
cell carcinoma (HNSCC). We report that miR-203, a
miRNA that triggers differentiation in multilayered
epithelia, inhibits multiple postextravasation events
during HNSCC lung metastasis. Inducible reactiva-
tion of miR-203 in already established lung metasta-
ses reduces the overall metastatic burden. Using
an integrated approach, we reveal that miR-203 in-
hibits metastasis independently of its effects on dif-
ferentiation. In vivo genetic reconstitution experi-
ments show that miR-203 inhibits lung metastasis
by suppressing the prometastatic activities of three
factors involved in cytoskeletal dynamics (LASP1),
extracellular matrix remodeling (SPARC), and cell
metabolism (NUAK1). Expression of miR-203 and
its downstream effectors correlates with HNSCC
overall survival outcomes, indicating the therapeutic
potential of targeting this signaling axis.
INTRODUCTION
Adult stratified epithelia are maintained by a balance between
stem cell self-renewal and differentiation (Arwert et al., 2012;
Blanpain and Fuchs, 2006). As emerging neoplastic drivers,
stem cells and the factors that control their biology are of thera-
peutic relevance in carcinomas (Pardal et al., 2003). For
example, NOTCH1 and TP63 form a negative feedback loop in
epidermal stem cells, with NOTCH1 promoting differentiation
and TP63 inhibiting it (Nguyen et al., 2006). Inactivation of these
genes is associated with skin tumors in mice (Flores et al., 2005;
Nicolas et al., 2003) and head and neck squamous cell carci-
noma (HNSCC) in humans (Agrawal et al., 2011; Stransky
et al., 2011). Thus, disruption of the epithelial stem cell molecular
circuitry can play a driving role in malignant transformation of the
tissues they replenish.104 Cell Reports 9, 104–117, October 9, 2014 ª2014 The AuthorsHNSCC is the sixth most common cancer worldwide and has
had a 5-year overall survival rate of only50% for decades (Lee-
mans et al., 2011). Two-thirds of patients present with advanced,
locally invasive disease that recurs despite mainstay surgery or
chemo- and/or radiotherapy, thus creating a pressing need for
novel avenues of therapeutic intervention (Argiris et al., 2008).
Metastasis accounts for >90% of solid-cancer-related deaths
(Valastyan and Weinberg, 2011). Metastatic dissemination can
occur early in the evolution of a tumor, followed by extended
dormancy (Hu¨semann et al., 2008). Indeed, up to 40% of carci-
noma cases without clinical evidence of metastasis actually har-
bor disseminated tumor cells in the bone marrow (Pantel and
Brakenhoff, 2004). Thus, truly efficacious cancer therapeutics
must target already established metastases rather than just
inhibit tumor growth or dissemination (Valastyan and Weinberg,
2011).
miRNAs are small noncoding RNAs that posttranscriptionally
repress target mRNAs important for tissue homeostasis and
cancer (Lujambio and Lowe, 2012; Valastyan et al., 2009b).
Although our understanding of metastasis-relevant miRNAs
has advanced rapidly in well-studied malignancies such as
breast cancer (Valastyan et al., 2009a, 2010, 2011; Yi et al.,
2008), we know little about whether and how miRNAs modulate
metastasis in HNSCC. Therefore, we employed functional in vivo
approaches to identify miR-203 as a potent negative regulator of
HNSCC metastasis by targeting a panel of prometastatic
effector proteins (Yi et al., 2008).RESULTS
A Screen of miRNAs in HNSCC Identifies miR-203 as a
Metastasis Suppressor
To uncover endogenousmiRNAs that reduce the lungmetastatic
potential of HNSCC, we employed the screening approach
shown in Figure 1A. Using a panel of 17 primary, early-passage
human HNSCC cell lines from surgically resected tumors, we
assayed the expression of 15 miRNAs identified as coordinately
deregulated in published expression profiles of HNSCC (see
the Supplemental Experimental Procedures). We identified
five downregulated miRNAs (miR-26b, miR-125b, miR-203,
miR-218, and miR-373) and one upregulated miRNA (miR-15a)
when we compared miRNA expression in HNSCC cells versus
primary human keratinocytes (Figure 1A). miR-133a and miR-
133b were not detected in any lines.
To assess the function of the deregulated miRNAs in HNSCC,
we generated two YFP-luciferase-expressing cell lines—SCC13
(established facial SCC; Rheinwald and Beckett, 1981) and
SJG15 (primary lingual SCC; Goldie et al., 2012)—in which we
knocked down miR-15a or stably overexpressed miR-26b,
miR-125b, miR-203, miR-218, or miR-373 using lentiviral ap-
proaches (Figure S1A). No antiproliferative or cytotoxic effects
were observed in vitro in adherent cultures (Figure S1C).
We explored the function of these miRNAs in an in vivo ortho-
topic tongue xenograft assay that recapitulates aspects of hu-
man HNSCC (Goldie et al., 2012). SCC13 cells were injected
into the lingual mucosa of nonobese diabetic/severe combined
immunodeficient interleukin-2 receptor-g chain null (NSG) mice
(Figure 1A), and noninvasive, luciferase-based bioluminescent
imaging was used to monitor disease progression (Kim et al.,
2010; Tiffen et al., 2010). Xenografting 105 miRNA expressing
SCC13 cells revealed that overexpression of miR-203 and
knockdown of miR-15a modestly reduced tumor burden after
26 days compared with control. The other miRNAs did not affect
tumor burden (Figures 1B and S1D).
To measure metastatic dissemination from the primary tu-
mors, we imaged the lungs of tumor-bearing mice ex vivo at
26 days (Figure 1C). Overexpression of miR-26b and miR-218
enhanced metastatic dissemination, whereas the other four
miRNAs had no significant effect (Figure 1D). Since the aim of
the screen was to identify antimetastatic miRNAs, we did not
analyze miR-26b and miR-218 further.
To examine metastatic colonization independently of primary
tumor growth, we intravenously injected miRNA-expressing
SCC13 and SJG15 cells into NSG mice (Figure 1A). Overex-
pression of miR-203 or knockdown of miR-15a suppressed
metastasis in both cell lines, as determined by endpoint lung
metastatic burden, ex vivo fluorescence microscopy, and histol-
ogy (Figures 1E and S1E–S1H). miR-125b and miR-373 were
excluded from further analysis because their effects were not
consistent between SCC13 and SJG15 cells. Since miR-15a is
a tumor suppressor (Aqeilan et al., 2010), we expressed miR-
15a in otherwise nonmetastatic, miR-15alow SCC25 cells (estab-
lished lingual SCC; Rheinwald and Beckett, 1981; Figure S1B).
Overexpression of miR-15a did not enhance lung metastatic
colonization by SCC25 cells (Figure 1F), so we did not analyze
this miR further.
With miR-203 presenting the most compelling case as a
metastasis-suppressor gene, we explored its clinical relevance
in a cohort of 219 HNSCC patients from The Cancer Genome
Atlas (TCGA) (data available through the TCGA Data Portal; Fig-
ure 1G). The 5-year survival rate of miR-203-low patients was
36%, compared with 70% for miR-203-high patients, indepen-
dently of primary tumor size (T1/T2 versus T3/T4). Patients with
miR-203-low tumors also exhibited significantly more lymph
node-positive disease and lymphovascular invasion—two major
prognostic factors for eventual distant metastasis. Hence, miR-
203 is a prognostic indicator of overall survival and propensity for
metastasis.Using high-resolution copy-number data for 322 HNSCC
patients from TCGA, we detected a copy-number alteration
(CNA) harboringmiR-203 thatwas focally deleted in 15%of cases
(Figure S2B). This CNA included several genes that have been
implicated in suppressing epithelial tumorigenesis and/or metas-
tasis, such as DICER1 (Martello et al., 2010) and ELF5 (Chakra-
barti et al., 2012). The miR-203 locus was also deleted in cuta-
neous melanoma (34% of cases), lung adenocarcinoma (29% of
cases), and glioblastomamultiforme (28%of cases) (Figure S2C).
Therefore, deregulation of miR-203 in HNSCC (and potentially
other tumor types) is due, at least in part, to focal CNAs that
alter multiple tumor- and/or metastasis-suppressive pathways.
Effect of miR-203 Expression on Primary Tumor Growth
To examine miR-203 expression in vivo, we performed in situ
hybridization in 28 cases of primary and/or metastatic skin
SCCs with matched normal skin from the same patients, and
three further cases of skin SCC (total of 11 patients; Table S1).
Whereas miR-203 was strongly expressed in the suprabasal,
differentiated layers of normal epidermis, confirming previous
reports (Yi et al., 2008), its expression was 35-fold lower in
matched cutaneous SCCs (Figure 2A).
We found that miR-203 significantly reduced both the average
number and size of spheres formed by SCC13 in soft agar (Fig-
ure 2B and data not shown), consistent with the observation that
when 105 cells were injected into the tongue, miR-203 reduced
tumor growth (Figure 1B). To assess the impact on tumor growth
in more detail, we xenografted 104 SCC13 cells expressing
miR-203 or scrambled control hairpin (SCR) and monitored
tumors for up to 50 days (Figure 2C). We confirmed miR-203
expression by in situ hybridization (Figure S3B). The reduction
in tumor size upon expression of miR-203 was due to a lag in
the initial rate of growth, and from week 2 onward the rate of
tumor growth was comparable to that in control SCC13 cells
(Figures 2C and S3A).
To investigate whether miR-203 affected the proportion of
cells that were capable of initiating primary tumors, we per-
formed a limiting dilution analysis (LDA) (Lapouge et al., 2012)
in which 104, 103, 100, or 10 SCC13 SCR or miR-203 cells
were injected into the tongue (Figure 2D). No difference in tumor
incidence was observed between miR-203- and SCR-express-
ing cells (Figure 2D). There was, however, a lag in tumor growth
phase at all seeding densities (Figures 2C and S1D; data not
shown).
We conclude that miR-203 overexpression does not affect the
number of tumor-initiating cells or the overall tumor growth rate,
but causes a delay before tumor growth becomes established,
which results in a reduction in tumor size. This may explain the
lack of a correlation between T stage and miR-203 expression
in HNSCC patients, since, at least in xenografts, the effect on tu-
mor size is more marked at early time points (Figure 1G).
miR-203 Expression Inhibits Lung Metastasis
We measured the circulating tumor DNA content by extracting
whole peripheral blood 50 days after tongue xenografting (Fig-
ure 2C) and determined the levels of human AluJ or hLine1
repeat elements by quantitative PCR (qPCR) (Figure 2E). There
was no difference in circulating tumor DNA content betweenCell Reports 9, 104–117, October 9, 2014 ª2014 The Authors 105
Figure 1. Candidate-Gene-Based Functional In Vivo miRNA Screen
(A) Schematic of the pipeline for an in vivo functional screen to identify miRNAs that regulate HNSCC lung metastasis. Heatmap of log2 normalized qRT-PCR
expression data for 13 miRNAs in 17 human HNSCC lines normalized to normal human oral keratinocytes. Data were clustered using cosine statistics.
(B) Fold primary tumor growth generated by 105 SCC13 cells individually expressing the indicated miRNA vectors after 26 days. Whiskers indicate min/max and
the horizontal bar is the median, with n = 4–5 per group.
(C) Representative ex vivo bioluminescent images of whole lungs at necropsy (day 26). Scale bar represents 3 mm.
(D) Total ex vivo lung photon flux at endpoint (day 26). The horizontal line indicates mean, with n = 5 per group.
(E) Lung metastatic burden resulting from tail-vein injection of SCC13 or SJG15 cells in which the levels of six miRNAs were individually modulated. Data are
means ± SEM, n = 5 per group.
(legend continued on next page)
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mice bearing miR-203 or control SCC13 primary tumors (Fig-
ures 2E and S3C). However, ex vivo bioluminescence and fluo-
rescence imaging of lungs showed that miR-203-expressing
SCC13 cells founded smaller metastases than control cells (Fig-
ure 2F). Therefore, miR-203 does not alter the ability of cells from
the primary tumor to enter the circulation, but does hamper their
capacity to expand following engraftment in the lungs.
Consistent with these results, miR-203-expressing SCC13
and SJG15 cells exhibited a dose-dependent impairment in
lung colonization following tail-vein injection (Figure 2G). Expres-
sion of miR-203 significantly prolonged the time required for
SCC13 and SJG15 cells to reach input levels of lung biolumines-
cence, suggesting that miR-203 extended the dormancy phase
of engrafted cells (Figure 2G), mirroring the phenotype observed
in primary tumors (Figure 2C). Expression of miR-203 signifi-
cantly increased survival time (Figure 2H) and reduced the
endpoint lung metastatic burden (Figure 2I). This was confirmed
by ex vivo fluorescence microscopy and anti-keratin-14 immu-
nohistochemistry (IHC) of lungs (Figure 2J and S3E). Whereas
control SCC13 and SJG15 cells colonized the majority of the
lung area, cells expressing miR-203 only generated small meta-
static lesions or remained as clusters of individual cells (Fig-
ure S3F). We confirmed that miR-203 expression was sustained
in SCC13 lung metastases (Figure S3G). Taken together, these
data suggest that miR-203 regulates the outgrowth of tumor
cells once they have reached the lung.
We next asked whether endogenous miR-203 was necessary
to prevent metastasis. For this purpose, we used SJG27 cells
(primary lingual SCC), which express high levels of miR-203
and do not readily metastasize. Silencing miR-203 (miR-203
KD) in YFP-luciferase-labeled SJG27 cells did not impair prolifer-
ation in vitro (Figures S3H and S3I), but did enhance formation of
clonogenic spheres in soft agar (Figure 3A). When injected into
the circulation of mice, miR-203 KD SJG27 cells were signifi-
cantly more proficient at forming lung metastases over 65 days
compared with control cells (Figure 3B). Knockdown of miR-
203 reduced the time to metastatic progression (Figure 3C)
and enhanced the total lung metastatic burden (Figure 3D).
Ex vivo fluorescence microscopy and anti-keratin-5 IHC showed
thatmiR-203 KD cells generatedmore numerous and larger nod-
ules than control cells (Figure 3E). Clusters of individual cells
were visible in control, but not miR-203 KD, lungs, further sug-
gesting a role for miR-203 in maintaining dormancy (Figure S3J).
We conclude, on the basis of miR-203 knockdown and over-
expression, that miR-203 inhibits lung metastasis of HNSCC.
miR-203 Regulates Multiple Postextravasation Events
and Inhibits Established Metastases
We next used a doxycycline (dox)-inducible system to tempo-
rally control miR-203 expression (Figures 4A, 4B, and S4A).(F) Time course of experimental lungmetastasis by SCC25 cells overexpressingm
per group.
(G) Kaplan-Meier plots for overall survival of 219 HNSCC patients from the TCG
n = 191) cohorts based onmiRNAseq read counts. ThemiR-203-high and -low pat
(positive or negative), lymphovascular invasion (positive or negative), and primar
*p < 0.05; **p < 0.01; ***p < 0.001 (nonparametric Mann-Whitney test). For Kapla
patient cohort comparisons, p values were calculated using Fisher’s exact test.Dox-inducible miR-203 expression did not affect in vitro prolifer-
ation of adherent cells (Figure S4B), but reduced the anchorage-
independent growth of SCC13 cells in soft agar (Figure S4C),
consistent with the effect of constitutive expression (Figure 2B).
We activated miR-203 expression at defined time points
following intravenous injection of SCC13 cells (Figure 4B).
Expression of miR-203 was either never induced (mimicking
cells lacking miR-203), induced before intravenous injection (day
0, phenocopying constitutive miR-203 expression), or induced
10 (dormancy phase of engrafted cells), 29 (establishment of mi-
crometastases), or 56 days (macrometastatic colonization) after
injection.
Animals injected with scrambled control cells that were never
induced or induced from day 0, 10, 29, or 56 all had similar dis-
ease burdens, arguing against any effects of the dox-rich diet
(Figures 4C–4E and data not shown). An examination of RFP
andGFP signals from lungmetastases in each cohort of animals,
as well as in situ hybridization for miR-203, confirmed dox-
dependent, sustained expression of miR-203 in vivo (Figures
S4D–S4F and data not shown).
Activation of miR-203 for the duration of the experiment re-
sulted in a 95% inhibition of endpoint lung metastatic burden
(Figures 4C and 4D). Reexpression of miR-203 from 10 or
29 days was sufficient to block 80% of the endpoint lung
metastatic burden (Figures 4C and 4D). Ex vivo fluorescence
microscopy of lungs confirmed that reintroduction of miR-203
substantially reduced the number and size of lung metastases
(Figure 4E). Although it was not statistically significant, animals
in which miR-203 was induced for only the final 2 weeks of the
experiment had 40% lower lung metastasis (Figures 4C and
4D) accompanied by a moderate reduction in lesion size and
number (Figure 4E).
We next investigated whether miR-203 affects cancer cell
extravasation across the lung vasculature in vivo (Figure 4F).
Thirty hours after intravenous injection, multiphoton confocal
imaging of individual GFP+ tumor cells and tomato lectin-labeled
blood vessels revealed that a similar proportion (90%) of
control and miR-203-expressing SCC13 cells had successfully
extravasated (Figure 4G).
We conclude that miR-203 inhibits lung metastasis by inhibit-
ing exit from dormancy, rather than by preventing migration from
the primary tumor or entry into the lung.
miR-203 Induces Mutually Exclusive Transcriptomic
Landscapes Characteristic of Keratinocyte
Differentiation and Poorly Metastatic Cells
To probe the mechanisms by which miR-203 regulates metas-
tasis, we performed genome-wide expression profiling and
gene set enrichment analysis (GSEA) of miR-203-expressing
SCC13 and SJG15 cells versus scrambled controls. Genome-iR-15a or control vector for 119 days. Log10 y axis, data aremeans ±SEM, n = 5
A cohort partitioned into miR-203-high (red, n = 28) and miR-203-low (blue,
ient cohorts were analyzed for the proportion of caseswith lymph node disease
y tumor T-stage, which is a measure of tumour state and size.
n-Meier plots, p values were calculated using a log rank Mantel-Cox test. For
See also Figure S1.
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Figure 3. Silencing Endogenous miR-203 Enhances Lung Metastasis
(A) In vitro soft-agar assay quantified at the first and second passages. Data are means ± SEM, with representative wells shown; ***p < 0.001 calculated using
two-tailed Student’s t test.
(B) Time course of experimental lung metastasis of miR-203 knockdown (KD) and control SJG27 cells over 65 days. Log10 y axis; data are mean ± SEM; n = 5 per
group.
(C) Kaplan-Meier plots for time to progression of lungmetastasis of SJG27 SCR andmiR-203-KD groups; p values were calculated using the log rankMantel-Cox
test.
(D) Lung metastasis by control and miR-203-KD SJG27 cells at day 65. Data are mean ± SEM; n = 5 per group; **p < 0.01 calculated using the nonparametric
Mann-Whitney test.
(E) Representative whole-mount GFP fluorescence microscopy images and matched keratin-5 IHC of metastatic lungs. Scale bar represents 2 mm.
See also Figure S3.wide expression changes elicited by miR-203 were negatively
enriched for signatures of metastasis in primary human HNSCC
arising in various anatomical locations within the aerodigestiveFigure 2. miR-203 Inhibits Experimental Lung Metastasis
(A) Representative in situ hybridization (red signal) for miR-203 and scrambled c
terstained with DAPI nuclear label. Scale bar represents 50 mm. Adjacent panel: qu
(B) Anchorage-independent soft-agar assay. GFP+ spheres were quantified after
(C) Fold primary tumor growth: 104 control and miR-203 expressing SCC13 cell
nescent imaging. Raw photon flux was normalized to input levels and presented
(D) Limited dilution analysis: 104, 103, 100, and 10 control and miR-203-expressin
over baseline) was determined by bioluminescent imaging and tumors were mon
(E) In vivo tumor cell intravasation was inferred by using qRT-PCR for human-spe
blood. n = 10 (SCR), n = 9 (miR-203).
(F) Whole-mount lung fluorescence images from representative animals in (D). Sca
Quantification of lung metastasis by bioluminescence; data are means ± SEM; n
(G) Lung metastatic colonization time course for SCC13 cells expressing high (n
miR-203 or scrambled control hairpin (n = 5 each). Log10 y axis. Data are means
(H) Kaplan-Meier analysis for time to progression of lung metastasis. SCC13 SC
(I) Endpoint lung metastatic burden of animals from (F) injected with miR-203 ex
animals. Data are means ± SEM.
(J) Representative whole-mount GFP fluorescencemicroscopy images ofmetasta
bar represents 2 mm.
*p < 0.05; **p < 0.01; ***p < 0.001 calculated using the nonparametric Mann-Whit
rank Mantel-Cox test. The p values for the soft-agar assay were calculated usingtract (Cromer et al., 2004; O’Donnell et al., 2005; Rickman
et al., 2008; Figure 5A). A similar negative enrichment between
miR-203 and metastasis signatures was also found inontrol probe in normal human skin (n = 28) and malignant SCC (n = 31) coun-
antification of miR-203 signal intensity in normal skin versus SCC. Log10 y axis.
3 weeks. Data are means ± SEM.
s were injected into the tongue and tumor growth was monitored by biolumi-
as mean ± SEM; n = 10 per group.
g SCC13 cells were injected into the tongue. Tumor incidence (5-fold increase
itored for up to 70 days (n = 9).
cific AluJ repeat elements present in circulating tumor cells within 200 ml whole
le bar represents 2 mm; left panels at 23 and right panels at 83magnification.
= 7 (SCR), n = 6 (miR-203).
= 10) or low miR-203 (n = 5) and relevant controls, and SJG15 cells expressing
± SEM.
R (n = 15) and miR-203 groups (high and low; n = 15) were pooled.
pressing SCC13 cells (day 78) and SJG15 cells (day 91) normalized to control
tic lung fields generated bymiR-203 and control SCC13 and SJG15 cells. Scale
ney test. The p values for the Kaplan-Meier plots were calculated using the log
the two-tailed Student’s t test. See also Figures S2 and S3.
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Figure 4. Inducible Restoration of miR-203
(A) Schematic representation of the dox-inducible miR-203 vector.
(B) Dox-mediated approach for reexpressing miR-203 following intravenous inoculation of SCC13 cells. Images represent single cells, micrometastases, and
macrometastases (left to right) in the lung following tail-vein injection. Scale bar represents 500 mm.
(C) Time course of experimental lung metastases formed by inducible control (SCR) and miR-203-expressing SCC13 in animals on normal or dox-rich diets. Day
indicates when the diet was switched to dox-rich. Log10 y axis; data are means ± SEM; n = 4–5 per group.
(D) Lung metastasis at endpoint (day 70) of noninduced or induced control and miR-203 SCC13 groups. Data are means ± SEM; n = 4–5 per group; **p < 0.01
calculated using nonparametric Mann-Whitney test relative to noninduced miR-203 animals. Differences between SCR groups and noninduced miR-203 are
nonsignificant.
(E) Representative whole-mount ex vivo GFP fluorescence microscopy images of metastatic lungs at day 70. Scale bar represents 3 mm.
(legend continued on next page)
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melanoma, breast, prostate, and endometrial tumors, all of
which have a tendency to metastasize (data not shown).
Together, these results suggest that miR-203 enforces a tran-
scriptional landscape in human HNSCC cells that is restrictive
for metastasis.
GSEA also revealed that signatures of human keratinocyte dif-
ferentiation were positively enriched in miR-203-expressing
HNSCC cells (Kretz et al., 2012; Mulder et al., 2012; Sen et al.,
2010; Figures 5A and 5B). However, there was no overlap be-
tween the core genes driving the metastasis and differentiation
signatures (Figure 5C). This suggests that miR-203 usesmutually
exclusive genetic strategies to prime the transcriptional land-
scape of HNSCC cells toward a poorly metastatic cell state
and a differentiated state. In support of this prediction, there
was no difference between control and miR-203-expressing
SCC13 tongue tumors and lung metastases in expression of
markers of undifferentiated keratinocytes, including keratin-5,
keratin-14, a6-integrin, and p63. There was no difference in
E-cadherin expression, and all tumors were negative for the
epithelial-mesenchymal transition (EMT) markers N-cadherin
and vimentin, with the exception of a few cells at the invasive
edge (Figures S5A and S5B; cf. Taube et al., 2013). There was
also no difference in expression of the keratinocyte differentia-
tion markers involucrin, keratin 10, and loricrin (Figures S5C
and S5D), or in markers of proliferation (Ki67 and phospho-his-
tone H3), apoptosis (cleaved-caspase 3 positive), or vascular
density (Figures S6A–S6C).
Hence, although miR-203 primed the transcriptional land-
scape of HNSCC cells toward a differentiated state, primary
tumors and lung metastases did not exhibit alterations in differ-
entiation status in vivo. These results suggest that the mecha-
nism by which miR-203 controls metastasis is distinct from its
prodifferentiation function in normal epidermis (Yi et al., 2008).
miR-203 Directly Targets a Cohort of Genes
Upregulated in HNSCC
To identify prometastatic miR-203 target genes, we used an in-
tegrated genomics, bioinformatics, and experimental approach
(Figure 5D). We curated our microarray expression data for
genes significantly downregulated by miR-203 and overlapped
these hits (171 genes) with a list of 993 miR-203 predicted target
genes from 11 publically available algorithms. To enrich for rele-
vance in human HNSCC, we filtered the 13 hits through Onco-
mine (Rhodes et al., 2007) and the Human Protein Atlas (Uhlen
et al., 2010), and discovered four genes (LASP1, NUAK1,
SPARC, and THBS2) that were upregulated in HNSCC speci-
mens relative to normal mucosa. Furthermore, we observed tu-
mor-specific upregulation of LASP1, NUAK1, SPARC, and
THBS2 in an independent cohort of 24 oral SCC patients not
contained in Oncomine (Figure 5F; Rhodes et al., 2007). Genes
associated with the actions of miR-203 in other cancers, such(F) Experimental strategy to quantify cancer cell extravasation across the lung v
travasated (out) or are trapped within the lumen of pulmonary blood vessels la
represents 10 mm.
(G) Proportion of cells in or out of lung vasculature at 30 hr after intravenous injecti
counted per mouse.
See also Figure S4.as BIRC5 (Saini et al., 2011), SNAI2 (Ding et al., 2013), P63 (Yi
et al., 2008), and c-Jun (Sonkoly et al., 2012), were not enriched
in our samples.
To validate the results of our analysis, we showed that overex-
pression of miR-203 led to downregulation of LASP1, NUAK1,
SPARC, and THBS2 in SCC13 and SJG15 cells (Figure 5E).
Dox induction of miR-203 in SCC13 and SJG15 cells led
to downregulation of LASP1, NUAK1, and SPARC, but not
THBS2 (Figure 5G).
We focused on LASP1, NUAK1, and SPARC because of
their involvement in metastasis-relevant processes such as
cytoskeletal dynamics, energy metabolism, and extracellular
matrix remodeling, respectively, and their previously described
roles in cancer (Liu et al., 2012; Minn et al., 2005; Traenka
et al., 2010). To determine whether or not LASP1, NUAK1,
and SPARC are direct miR-203 targets, we cloned the 30
UTRs into a luciferase reporter construct. The 30 UTR of
TP63, a known downstream target of miR-203 (Yi et al.,
2008), served as a positive control. Transfection of exogenous
miR-203 molecules (mimics) into 293T cells led to specific up-
regulation of miR-203 levels (Figure 5H). miR-203 mimics
repressed the LASP1, NUAK1, SPARC, and TP63 30 UTR re-
porters, while mutation of the various miR-203 binding sites
blocked miR-203-mediated regulation of each 30 UTR (Fig-
ure 5I). Western blotting showed a miR-203-dependent reduc-
tion in LASP1, NUAK1, and SPARC protein levels (Figure 5J).
Moreover, we found significant negative correlations between
RNA sequencing (RNAseq) read counts of miR-203 and each
of its three direct targets, but not TP63, across 225 HNSCC
patients in TCGA (Figure S2A). We thus confirmed LASP1,
NUAK1, and SPARC as direct target genes of miR-203 in hu-
man HNSCC.
LASP1, NUAK1, and SPARC Are Functionally Important
Prometastatic Downstream Effectors of miR-203 that
Are Prognostic of Overall Survival in HNSCC
To investigate the functional contribution(s) of LASP1, NUAK1,
and SPARC to miR-203-induced inhibition of metastasis, we
conducted genetic rescue experiments in vivo (Figure 6A).
We engineered control and miR-203 expressing SCC13 cells
to stably express all 16 possible combinations of miRNA-insen-
sitive cDNAs (lacking 30 UTRs) encoding LASP1, NUAK1, and
SPARC, and validated correct target gene reconstitution by
western blotting (Figure 6B). The levels of exogenous protein
expressed were sufficiently high that endogenous NUAK1
and SPARC (Figure 5J) could not be seen on the blots
(Figure 6B).
All 16 SCC13 populations were intravenously injected into
mice and lung metastasis was monitored for up to 88 days (Fig-
ures 6C, S6D, and S6E). Consistent with our earlier findings (Fig-
ure 2), SCC13 cells expressing miR-203 together with threeasculature in vivo. Examples of GFP+ SCC13 cells that have successfully ex-
beled in red (in) and outlined with a dashed white line are shown. Scale bar
on. Data are mean% ± SEM, with n = 3 per group. A total of 127–136 cells were
Cell Reports 9, 104–117, October 9, 2014 ª2014 The Authors 111
(legend on next page)
112 Cell Reports 9, 104–117, October 9, 2014 ª2014 The Authors
empty-vector controls (3xEV) did not colonize the lungs,
whereas 3xEV SCC13SCR cells generated numerousmacrome-
tastatic lesions (Figure 6C). Overexpression of SPARC or NUAK1
alone led to a small increase in metastasis of miR-203 cells,
whereas overexpression of LASP1 alone caused a pronounced
stimulation, which was comparable to overexpressing all three
proteins (Figures 6C, S6E, and S6E). Overexpression of LASP1
and/or SPARC, or combined expression of LASP1, SPARC,
and NUAK1 did not enhance metastasis of SCR SCC13 cells
(Figures 6C–6F, S6D, and S6E). Unexpectedly, when NUAK1
was expressed alone or in combination with SPARC or LASP1,
SCR SCC13 cells produced fewer metastases (Figures 6F and
S6E).
Individual or combined reintroduction of NUAK1, SPARC, and/
or LASP1 was sufficient to bolster the lung metastatic coloniza-
tion by SCC13 expressing miR-203 (Figure 6C–6F). NUAK1,
SPARC, and LASP1 promoted exit from dormancy (Figure 6D)
and overt pulmonary colonization, increasing the lungmetastatic
burden by 7-fold, 10-fold, and 53-fold, respectively (Figures 6E
and 6F). Thus, each miR-203 target promotes metastasis in the
presence of miR-203, with the effect of LASP1 being most pro-
nounced. In addition, knockdown of LASP1 reduced the clono-
genic potential of SCC13 cells in vitro (Figures S6F and S6G),
recreating the phenotype observed when miR-203 is expressed
in the SCC13 cell line (Figure 2B).
The clinical relevance of the miR-203 target genes was
confirmed in patient data. High expression of LASP1, NUAK1,
and SPARC correlated with poor prognosis in both the TCGA
cohort and a separate publically available HNSCC cohort (Fig-
ures 6G and 6H; Cromer et al., 2004).
We conclude that miR-203 inhibits lung metastasis, not by
triggering differentiation, but by directly targeting the prometa-
static genes LASP1, SPARC, and NUAK1, which are prognostic
factors in human HNSCC.Figure 5. LASP1, SPARC, and NUAK1 Are Direct Target Genes of miR-
(A) GSEA plots showing negative enrichment of three signatures of genes upre
signatures of genes upregulated during primary human keratinocyte differentiat
control. NES, normalized enrichment score; FDR, false-discovery rate q value.
(B) GSEA as in (A) using the ranked gene list (top upregulated to most downregu
(C) Leading-edge analysis of genes driving enrichment of metastasis and differen
abbreviated to first letters only on the horizontal axis. The overlap score (0–1) indic
other signatures.
(D) Experimental and bioinformatics strategy to identify clinically relevant miR-20
expressing SCC13 and SJG15 cells was followed by enrichment for downregulat
and subsequently analysis of microarray and protein expression data sets in On
validation.
(E) Heatmap depicting log2 transformed expression levels of four candidatemiR-2
and miR-203-expressing SCC13 and SJG15 cells.
(F) Analysis of GSE31056 for LASP1, NUAK1, SPARC, and THBS2 expression (c
SCCs (23 samples); p values were calculated between normal and tumors using
(G) qRT-PCR for LASP1, NUAK1, SPARC, and THBS2 mRNA expression in SCC1
either not induced or induced for 3 consecutive days in vitro. Expression normal
(H) qRT-PCR expression of miR-15a and mi-20 in 293T cells transfected with 20 n
Expression was normalized to Ctrl miR. Data are means ± SEM.
(I) Luciferase reporter assays measuring the ability of transfected miR-203 to re
SPARC, and TP63 (positive control). Measurements are the ratios of firefly/ren
means ± SEM.
(J) Li-Cor western blots of whole-cell lysates (NUAK1, LASP1, and GAPDH) an
SCC13 cell cultures.
*p < 0.05, **p < 0.01, ***p < 0.001 calculated using unpaired Student’s t test. SeDISCUSSION
Our studies uncover miR-203 as a potent suppressor of key
postextravasation events during lung metastasis. Reintroducing
miR-203 into already established pulmonary nodules elicits their
regression, suggesting the potential for therapeutic modalities
aimed at activating miR-203 in cancer cells to treat metastatic
HNSCC.
Recent evidence suggests that cancer cells hijack normal stem
cell self-renewal signaling pathways to generate and propagate
tumors in vivo (Reis et al., 2011). If so, coaxing cancer cells to
differentiate may inhibit tumor growth and metastasis. Although
miR-203 promotes differentiation of normal epidermal stem cells
(Jackson et al., 2013; Yi et al., 2008), our study shows that it does
not promote carcinoma differentiation in vivo. Instead, miR-203
controls HNSCC metastasis by targeting a network of prometa-
static proteins, including LASP1, SPARC, and NUAK1. Thus,
we propose that miR-203 undergoes a context-dependent func-
tional switch from regulating normal differentiation to acting as a
differentiation-independent roadblock to metastasis.
It is known that the genetic and epigenetic alterations sus-
tained by host cells during malignant transformation alter the
repertoire of mRNA species available for targeting by miRNAs
(Lujambio and Lowe, 2012). Thus, miRNAs can perform
cellular-context-dependent functions driven by different cohorts
of downstream effectors. For example, miR-126 inhibits breast
cancermetastasis either bymodulating the primary tumormicro-
environment (Zhang et al., 2013) or by inhibiting lung metastatic
colonization (Png et al., 2012) in mouse or human breast cancer
models, respectively. As such, the rewiring of miR-203 function
from regulating differentiation to inhibiting metastasis is likely
to be explained by changes in target gene selection from differ-
entiation-relevant proteins, such as TP63, to metastasis-pro-
moting factors, such as LASP1, SPARC, and NUAK1.203
gulated in metastatic HNSCC (top row), and positive enrichment with three
ion in vitro (bottom row), in miR-203-expressing SJG15 cells compared with
lated) of genes in BMP2/7-treated keratinocytes compared with control.
tiation signatures in miR-203-expressing SJG15. Signatures on the vertical are
ates the degree to which leading-edge genes in each signature are shared with
3 target genes. Microarray expression profiling of stable miR-203 and control
ed direct targets using publically available miRNA target prediction algorithms,
comine and the Human Protein Atlas to obtain four candidate target genes for
03 target genes in themicroarray experiments, validated by qRT-PCR in control
ounts) in normal tissue (24 samples), oral SCC margins (49 samples), and oral
the nonparametric Mann-Whitney test.
3 and SJG15 cells expressing inducible miR-203 or control vector. Cells were
ized to GAPDH. Data are means ± SEM.
M negative control miRNA (Ctrl miR) or miR-203 for luciferase reporter assays.
press wild-type (left) and mutant (right) 30 UTR sequences of LASP1, NUAK1,
illa luminescence readings relative to control miRNA transfectants. Data are
d conditioned medium (SPARC) from control (SCR) and miR-203-expressing
e also Figures S5 and S6.
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Our mechanistic studies identify LASP1, SPARC, and NUAK1
as important direct downstream effectors for miR-203-mediated
inhibition of HNSCC metastasis. Prior studies have shown that
these proteins promote cancer cell migration and invasion
in vitro, promote tumor progression and/or metastasis in vivo,
and correlate with poor overall survival in diverse carcinomas
(Chang et al., 2012; Chin et al., 2005; Davis et al., 2008; Liu
et al., 2012; Minn et al., 2005; Suzuki et al., 2004; Traenka
et al., 2010; Viticchie` et al., 2011). We speculate that LASP1,
NUAK1, and SPARC promote postextravasation survival and/
or engraftment, shorten dormancy, and bolster overt pulmonary
colonization by HNSCC cells.
Our data indicate that miR-203 is an upstream governor of
several distinct cellular pathways that converge to enforce a
poorly metastatic cell state, and highlight the importance of
cellular context in determining the effects of a specific miRNA
on metastasis. Indeed, miR-203 regulates tumor progression in
breast and prostate cancer, but the targets of its action are
very distinct among tissue types. In advanced metastatic pros-
tate cancer, miR-203 targets BIRC5 (Saini et al., 2011), whereas
in breast cancer metastasis it targets SNAI2 (Ding et al., 2013).
This suggests that miR-203 not only functionally switches be-
tween tissue homeostasis and cancer progression, as shown
here, but also switches targets depending on the cancer type.
In conclusion, our studies highlight miR-203 and its effectors
as promising routes for therapeutic intervention in metastatic
HNSCC. Unlike most anticancer agents and antimetastatic stra-
tegies currently in clinical trials (Valastyan and Weinberg, 2011),
miR-203 can antagonize metastasis even after cancer cells have
seeded the lung and formed clinically advanced nodules. In light
of the development of targeted strategies to deliver nucleic acids
into tumor cells (Davis et al., 2008), we envision the potential
value of usingmiR-203mimetics to alleviate otherwise therapeu-
tically intractable metastatic HNSCC.
EXPERIMENTAL PROCEDURES
Cell Lines
SCC13, SCC25, SJG cell lines, and normal keratinocytes were cultured in FAD
medium under standard conditions. Work with human material was either car-
ried out in compliance with the UK Human Tissue Act (2004) and approved byFigure 6. LASP1, SPARC, and NUAK1 Can Overcome miR-203 Metasta
(A) Schematic model for miR-203-driven suppression of lung metastatic fitness i
miR-203-insensitive LASP1, NUAK1, and SPARC in miR-203-expressing SCC13
(B) Li-Cor western blots of 16 different whole-cell lysates from control (SCR) and
combinations of LASP1, NUAK1, and SPARC cDNAs. GAPDH was used as a loa
(C) Time course of experimental lung metastasis generated by control (SCR) SCC
SPARC, or LASP1, or NUAK1, SPARC, and LASP1 together (N+S+L) over 88 day
Data were selected from the full set of combinations presented in Figure S6D.
(D) Kaplan-Meier plots for time to progression of lung metastasis of control and
cDNAs; p values were calculated using the log rank Mantel-Cox test; n = 4–5 pe
(E) Lung metastasis formed by 3xEV, NUAK1, SPARC, or LASP1, or NUAK1, SPA
SCRSCC13 cell line, analyzed at day 88.Whiskers indicate min/max and the horiz
were calculated using the nonparametric Mann-Whitney test in comparison with
(F) Representative whole-mount ex vivo GFP fluorescence microscopy images o
Scale bar represents 3 mm.
(G) Kaplan-Meier plots for overall survival of 272 HNSCC patients from the TCGA
counts; p values were calculated using the log rank Mantel-Cox test.
(H) LASP1, NUAK1, and SPARCmRNA expression was used to partition the GSE
Mantel-Cox test.the National Research Ethics Service (08/H0306/30) or according to the rec-
ommendations of the local ethics committee and the German Medical Council
for diagnostic tissue used in research.
Animal Studies
Tongue xenografting and experimental lung metastasis experiments were
performed as previously described (Goldie et al., 2012). Animal studies were
subject to Cancer Research UK and King’s College London ethical review
and performed in accordance with an approved UK Government Home Office
license. A dox-rich diet (Harlan)was used to inducemiR-203 expression in vivo.
Bioluminescent imaging was conducted using a Xenogen IVIS 200 system
(Perkin Elmer).
qRT-PCR, Microarrays, and GEO Data Sets
RNA was isolated using a miRNeasy Mini Kit (QIAGEN), and qRT-PCR was
performed using TaqMan probes (Life Technologies) and SYBR Green
primers. Genome-wide expression analysis was carried out on Illumina Hu-
man HT12 version 4 arrays. Microarray data sets GSE31056 and GSE2379
were downloaded from NCBI GEO. TCGA data were downloaded from
https://tcga-data.nci.nih.gov/tcga/ and http://www.broadinstitute.org/tcga/
home.
Statistical Analysis
An unpaired two-tailed Student’s t test (in vitro experiments) or a nonpara-
metric Mann-Whitney test (in vivo mouse experiments) was used for compar-
isons, with p < 0.05 considered significant. A log rank (Mantel-Cox) test
was used to compare survival curves and compute hazard ratios, and
Fisher’s exact test used to compare human cohorts on the basis of clinical
characteristics.
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